Physician profile
Shane E Keller
NPI 1194768911
$3,492.89
in general payments reported to CMS, 2019-2025
34 companies · $783 in 2025
The $783 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $81.86 · 2021: $61.94 · 2022: $472 · 2023: $938 · 2024: $1,043 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,763.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $627.14 | 2022-2025 | |
| Abbott Laboratories | $392.68 | 2023-2025 | Freestyle Libre 3, Octrode, Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $323.85 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $322.10 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $184.72 | 2020-2025 | Wegovy, Ozempic |
| Pfizer INC. | $181.10 | 2022-2025 | |
| Glaxosmithkline, LLC. | $159.83 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $148.80 | 2022-2025 | Otezla, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $100.03 | 2022-2025 | |
| Lilly USA, LLC | $93.90 | 2022-2025 | Jardiance, Kisunla, Mounjaro |
| Novartis Pharmaceuticals Corporation | $93.28 | 2022-2023 | |
| Corium, LLC | $92.27 | 2022-2023 | Azstarys |
| Gilead Sciences, INC. | $83.36 | 2022-2023 | |
| Exact Sciences Corporation | $83.08 | 2023-2025 | Cologuard Collection Kit |
| Collegium Pharmaceutical, INC. | $60.81 | 2025 | Jornay Pm |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $59.89 | 2023-2024 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $57.45 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Astellas Pharma US INC | $50.91 | 2024-2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $50.18 | 2024-2025 | Zoryve |
| Medtronic, INC. | $38.07 | 2023 | Intellis Adaptivestim, Vanta Adaptivestim |
| Inspire Medical Systems, INC. | $38.03 | 2023 | Inspire |
| Ethicon US, LLC | $28.04 | 2019 | |
| Nevro Corp. | $27.76 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $26.01 | 2022 | |
| Idorsia Pharmaceuticals US INC | $22.69 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $21.23 | 2024 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.11 | 2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $20.03 | 2024 | |
| Almatica Pharma LLC | $19.33 | 2021 | |
| Acerus Pharmaceuticals Corporation | $18.21 | 2022 | |
| Tolmar, INC. | $15.44 | 2025 | Jatenzo |
| Janssen Pharmaceuticals, INC | $14.62 | 2022 | |
| Supernus Pharmaceuticals, INC. | $13.72 | 2023 | Qelbree |
| Romark Laboratories, Lc | $3.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.